CMBA
SPRO icon

C.M. Bidwell & Associates’s Spero Therapeutics SPRO Stock Holding History

C.M. Bidwell & Associates’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-372
Closed -$6K – 603
2021
Q4 		$6K Hold
372
– – ﹤0.01% 421
2021
Q3 		$7K Hold
372
– – ﹤0.01% 416
2021
Q2 		$5K Buy
+372
New +$5.2K ﹤0.01% 469

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

C.M. Bidwell & Associates's SPRO Position: Q1 2022 in Review

C.M. Bidwell & Associates sold out of Spero Therapeutics (SPRO) in Q1 2022, closing a stake of 372 shares — an estimated $6K sold.

C.M. Bidwell & Associates first reported a position in SPRO in Q2 2021 and held it in 3 quarters. The position peaked at $7K in Q3 2021. 100 funds tracked by Wall St. Rank hold SPRO as of Q1 2022.

  • C.M. Bidwell & Associates reported no remaining Spero Therapeutics position as of Q1 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 372 Spero Therapeutics shares in Q1 2022, an estimated $6K.
  • C.M. Bidwell & Associates first reported a position in Spero Therapeutics in Q2 2021 and held it in 3 quarters.
  • C.M. Bidwell & Associates's Spero Therapeutics position peaked at $7K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.